As the post-pandemic world of work continues to evolve, so do recruiters’ strategies and tools for finding and engaging top talent. In 2023, we are seeing these seven trends:1. Employer branding is becoming an increasingly important factor in the recruitment…
ACADEMIA
Japan to Join NIH-Sponsored COVID-19 Trial for Gilead’s Remdesivir
Japan is set to join a multinational clinical trial launched by the US National Institutes of Health late last month for Gilead Sciences’ antiviral remdesivir for the treatment of the novel coronavirus disease COVID-19, a Japanese researcher said on March…
To read the full story
Related Article
- PMDA Updates Veklury Label to Allow Its Use in Moderate COVID-19
January 8, 2021
- Japan to Join NIH’s Remdesivir-Baricitinib Combo Trial for COVID-19
June 1, 2020
- Check Latest Info and Make Careful Decision on Veklury Use: PMDA Review Report
May 19, 2020
- Chuikyo OKs Special Mixed Care Scheme for Veklury
May 11, 2020
- Japan Approves Remdesivir as First Drug for COVID-19
May 8, 2020
- Gilead Japan Expected to Offer Remdesivir for Free for Now
May 7, 2020
- Gilead Files Remdesivir for COVID-19 in Japan
May 4, 2020
- Japan Likely to Take FDA’s Anticipated EUA as Cue for “Special” Remdesivir OK
May 1, 2020
- Japan to Quickly Utilize “Special Approval” Scheme for Remdesivir after It’s OK’ed Overseas: Minister
April 30, 2020
- Japan Might Approve Gilead’s Remdesivir for COVID-19 in May
April 28, 2020
- Gilead Japan to Seek Early Remdesivir Filing If Initial Data Prove Positive: Development Chief
April 16, 2020
- Gilead Launches PIII Remdesivir Trials for COVID-19 in Japan
April 15, 2020
- Gilead-Sponsored Remdesivir Trial Expected to Start This Month: Minister
April 3, 2020
- Gilead Launches PIII Studies for Remdesivir for COVID-19, Japan Included
February 28, 2020
ACADEMIA
- Japan Syphilis Cases on Track to Hit Record for Third Year in a Row
May 31, 2023
- CGP Assays Prior to Initial Treatment Would Have Little Impact on Health Finances: Professor
May 31, 2023
- Keep Public Funding for COVID Drugs to Get through This Winter: Academic Societies
May 25, 2023
- Osaka University Completes Transplants of iPS Cell-Derived Cardiac Cell Sheet
May 22, 2023
- OB/GYN Society Aims for Early Use of Oral Abortion Pill at Clinics without Beds
May 12, 2023
Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…